Biotech Partnership Massachusetts & the Netherlands
Strategic, multi-year market development initiative on Organ-on-a-Chip between the Netherlands and Switzerland.
MOITI Massachusetts Office of International Trade and Investment, MassBio, Massachusetts Life Sciences Center, The Termeer Institute, Ministerie van Economische Zaken en Klimaat, Vereniging Innovatieve Geneesmiddelen, Health Holland and hollandbio
In 2022, Massachusetts Life Sciences Center and Health Holland signed the Program of Cooperation (PoC) between the life sciences ecosystems of Massachusetts and the Netherlands. The activities vary from financing to healthcare systems, from start- and scale-ups to academic researchers. It includes activities like the Henri Termeer Transatlantic Connection Award, with an exchange program and fellowship program, workshops and an investor conference. The goal of this PoC is to further strengthen the Transatlantic Life Sciences Partnership.
From MoU to PoC
This Program of Cooperation (PoC) is an official follow-up of the earlier aspirations of the Memorandum of Understanding (MoU), which was signed in 2019. In the time being, signatories kept in touch with each other and kept thinking about the next steps for the partnership in two key stakeholder sessions in 2020 en 2021. Thanks to the ongoing contact and tide connections, especially made possibly by the Netherlands Innovation Network in Boston, we were able to sign the PoC.
Signatories
MOITI Massachusetts Office of International Trade and Investment, MassBio, Massachusetts Life Sciences Center, The Termeer Institute, Ministerie van Economische Zaken en Klimaat, Vereniging Innovatieve Geneesmiddelen, Health Holland and hollandbio together emphasize the strategic importance of the life sciences sector and will provide their support in accelerating the growth of their life sciences hubs and the global opportunities for companies and research organizations.
Opportunity!
Apply for the 2027 Termeer Fellows prescreen!
If you’re a first-time CEO of an early-stage life sciences company, this is your chance to enhance your leadership skills and join a peer cohort of passionate innovators driven by patient impact!
𝗘𝗹𝗶𝗴𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝗖𝗿𝗶𝘁𝗲𝗿𝗶𝗮 (must meet all to qualify)*:
𝘊𝘌𝘖 𝘌𝘭𝘪𝘨𝘪𝘣𝘪𝘭𝘪𝘵𝘺
• First-time, full-time CEO of a patient-focused therapeutic, diagnostic or medical device life science company.
𝘊𝘰𝘮𝘱𝘢𝘯𝘺 𝘌𝘭𝘪𝘨𝘪𝘣𝘪𝘭𝘪𝘵𝘺
𝘈𝘵 𝘵𝘩𝘦 𝘵𝘪𝘮𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘢𝘱𝘱𝘭𝘪𝘤𝘢𝘵𝘪𝘰𝘯:
• Has been legally incorporated for at least 2 years
• Has secured $500k-$40m in external funding raised (not including friends & family and/or founder capital) and in the process of raising a Seed round or beyond
Complete the prescreen here to be considered.
Deadline: September 30, 2026
Verbreed je netwerk
Bekijk de bijeenkomsten, missies en matchmakingsessies voor kennisuitwisseling, samenwerkingspartners en een nieuw netwerk.
